Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®

Rhea-AI Summary

Prestige Consumer Healthcare (NYSE:PBH) completed its acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare on June 15, 2026.

The deal is valued at $1.045 billion, or about $900 million net after anticipated $150 million tax benefits, and makes Breathe Right Prestige’s largest brand, adding a new product category.

Positive

• Closed acquisition of Breathe Right and other brands for $1.045 billion
• Net purchase price about $900 million after $150 million tax benefits
• Breathe Right becomes Prestige’s largest brand
• Acquisition adds a new product category for Prestige
• Deal funded with available cash plus new Term Loan B financing

Negative

• Use of new Term Loan B increases Prestige’s debt financing needs

News Market Reaction – PBH

-2.40%

-2.40% Session close to close

In the Jun 15 session, PBH declined 2.40%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms closing of the Breathe Right acquisition for $1.045 billion, or about $90...

Analysis

This announcement confirms closing of the Breathe Right acquisition for $1.045 billion, or about $900 million net of $150 million in anticipated tax benefits. It transitions an already-disclosed agreement into an owned asset, expanding Prestige into nasal strips and making Breathe Right its largest brand. Compared with earlier acquisition announcements that averaged a -4.9% move, investors may watch integration progress, category growth, and balance sheet impacts over coming quarters.

Key Figures

Purchase price: $1.045 billion Net purchase price: $900 million Tax benefits: $150 million

3 metrics

Purchase price $1.045 billion Gross consideration for Breathe Right and certain other brands

Net purchase price $900 million Consideration net of anticipated tax benefits

Tax benefits $150 million Anticipated tax benefits associated with the transaction

Previous Acquisition Reports

2 past events · Latest: May 13 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Earnings & acquisition	Negative	-11.3%	Fiscal 2026 revenue decline alongside announcement of LaCorium Health acquisition.
Mar 20	Acquisition agreement	Positive	+1.6%	Agreement to acquire Breathe Right portfolio with detailed valuation and financing plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent acquisition announcements averaged a -4.9% move, with one sizable selloff and one modest gain, suggesting investors have reacted cautiously to deal news.

Recent Company History

Over the last several months, Prestige used acquisitions as a key growth lever. On Mar 20, 2026, it agreed to buy Breathe Right and other brands for $1.045 billion, highlighting revenue and EBITDA contributions and term loan financing. On May 13, 2026, it reported fiscal 2026 results and announced the LaCorium Health acquisition for about $150 million. Those acquisition-tagged releases produced an average move of -4.9%, framing how markets have historically digested Prestige’s deal activity.

Key Terms

asset purchase agreement, term loan b

2 terms

asset purchase agreement financial

"The closing was finalized pursuant to the terms of the asset purchase agreement, announced on March 20, 2026..."

An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.

term loan b financial

"The Company financed the transaction with a combination of available cash on hand and a completed financing of a new Term Loan B."

A Term Loan B (TLB) is a large, syndicated loan made to a company that is typically sold to institutional investors rather than held by banks; think of it as a long-term mortgage from a group of investors with higher interest and smaller early payments. It matters to investors because it changes a company’s debt cost, repayment schedule and credit risk—factors that affect profit, cash flow and the market value of both the company’s equity and its traded debt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Right^® brand and certain other brands.

The closing was finalized pursuant to the terms of the asset purchase agreement, announced on March 20, 2026, under which Prestige agreed to acquire the Breathe Right^® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits valued at $150 million. Breathe Right^®, created in the 1990s, is an iconic #1 brand synonymous with the nasal strip category. It will become the company’s largest brand and represents expansion into a new category for Prestige.

The Company financed the transaction with a combination of available cash on hand and a completed financing of a new Term Loan B.

Further details regarding the transaction and benefits of Prestige are detailed in a presentation dated March 20, 2026 available on the Company’s website at https://ir.prestigebrands.com/.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right^® nasal strips, Monistat^® and Summer’s Eve^® women's health products, BC^® and Goody's^® pain relievers, Clear Eyes^® and TheraTears^® eye care products, DenTek^® specialty oral care products, Dramamine^® motion sickness treatments, Fleet^® enemas and glycerin suppositories, Chloraseptic^® and Luden's^® sore throat treatments and drops, Compound W^® wart treatments, Little Remedies^® pediatric over-the-counter products, Boudreaux’s Butt Paste^® diaper rash ointments, Nix^® lice treatment, Debrox^® earwax remover, Gaviscon^® antacid in Canada, and Hydralyte^® rehydration products and the Fess^® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com

FAQ

What did Prestige (NYSE:PBH) announce about the Breathe Right acquisition on June 15, 2026?

Prestige announced it completed the acquisition of the Breathe Right brand and certain other brands. According to Prestige, the closing follows an asset purchase agreement first announced on March 20, 2026, expanding its portfolio into a new category.

How much did Prestige pay to acquire the Breathe Right brand (PBH)?

Prestige agreed to acquire Breathe Right and certain other brands for $1.045 billion. According to Prestige, the net purchase price is about $900 million after anticipated $150 million in tax benefits related to the transaction.

How is Prestige financing the Breathe Right acquisition for PBH shareholders?

Prestige is financing the Breathe Right acquisition with a mix of available cash and a new Term Loan B. According to Prestige, this combination of internal funds and debt financing supports the $1.045 billion transaction value.

What does the Breathe Right acquisition mean for Prestige’s brand portfolio (NYSE:PBH)?

The acquisition makes Breathe Right Prestige’s largest brand by size. According to Prestige, Breathe Right also moves the company into a new nasal strip category, broadening its consumer healthcare product offerings and brand mix.

Who sold the Breathe Right brand to Prestige Consumer Healthcare (PBH)?

Prestige acquired the Breathe Right brand and certain other brands from Foundation Consumer Healthcare. According to Prestige, the transaction was executed under an asset purchase agreement originally announced on March 20, 2026, and closed on June 15, 2026.

Where can PBH investors find more details on the Breathe Right acquisition?

Investors can review a detailed transaction presentation dated March 20, 2026 on Prestige’s investor relations website. According to Prestige, this presentation outlines the acquisition terms and expected benefits from adding Breathe Right and related brands.